On February 3, 2021 The Canadian Glycomics Network (GlycoNet) reported $1.3 million in funding to 11 glycomics research projects (Press release, GlycoNet, FEB 3, 2021, View Source;utm_medium=rss&utm_campaign=new-glycomics-research-investments-from-glyconet-to-facilitate-a-resilient-recovery-for-canada [SID1234574551]). The investment is being leveraged through GlycoNet’s four funding streams—Collaborative Team, Strategic Initiative, Translational, and Clinical Partnerships—which aim to foster health innovations by gaining more understanding of the role of sugars in health and diseases. Industry collaborators, health foundations, and business partners are also co-investing $2.6 million for nearly $4 million in total funding towards areas of cancer, chronic diseases, infectious diseases, and neurodegenerative diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Part of this funding will support the development of an AAV9 gene therapy that is currently being developed by Dr. Jagdeep Walia from Queen’s University, in collaboration with Taysha Gene Therapies. Walia and his research team will conduct preclinical studies to test the safety and efficacy of the gene therapy when delivered intrathecally, with the intent of treating children with GM2A deficiency in clinical studies in the future.

Today’s announcement also includes funding for a team of researchers at the University of British Columbia (UBC) to develop enzymatic tools that will convert A and B type blood to the universal donor O type blood. The UBC researchers, led by Dr. Stephen Withers, will collaborate with the Canadian Blood Services and ABOzymes Biomedical to fully assess the efficacy of the enzymes, as well as the safety and compatibility of the converted blood. This project will help Canada build a strong foundation of sustainable national blood supplies and develop life-saving protocols for those who need blood transfusion in emergency situations.

Further, this funding will support the pilot project by McGill researcher, Dr. Donald Sheppard, and University of Alberta researcher, Dr. Todd Lowary to transform biomedicine for personalized antifungal therapies. In collaboration with Atara Biotherapeutics and Dr. Michel Sadelain, Director of the Center for Cell Engineering at Memorial Sloan Kettering Cancer Center, the research team will employ CAR T-cells technology to develop tools to treat invasive fungal infections that cause chronic lung diseases in patients undergoing chemotherapy and transplantation.

"As we navigate post-pandemic economic and social recovery, investments in science and innovations are essential to bring resilience and prosperity to our communities," said Dr. Warren Wakarchuk, Scientific Director of GlycoNet. "GlycoNet is proud to work with industry partners and cross-sectoral collaborators to drive glycomics research that will bring game-changing solutions to the future of Canadian healthcare and bioeconomy."

Glycomics research collaborations help Canada harness the potential of bio-innovations to build more self-reliant, sustainable, and prosperous communities. Through mobilizing knowledge and expertise in the study of carbohydrates, along with targeted investments to form strategic alliance among academic institutions, industry, and business partners, this funding will enable researchers to create homegrown solutions to power Canada to adapt to complex health challenges and build a resilient bioeconomy.

Quotes
"As we navigate post-pandemic economic and social recovery, investments in science and innovations are essential to bring resilience and prosperity to our communities. GlycoNet is proud to work with industry partners and cross-sectoral collaborators to drive glycomics research that will bring game-changing solutions to the future of Canadian healthcare and bioeconomy." – Warren Wakarchuk, Scientific Director, GlycoNet

"Many countries in the world have an imbalance between the ABO groups of those donating blood and the ABO groups of transfused blood. This is primarily because of an increased use of O blood when the blood group of the patient is not known. This can lead to blood shortages of group O blood. The technology developed by Dr. Withers allows for a possible solution to this problem by converting group A blood to group O to rebalance blood centre inventories." – Dr. Dana Devine, Chief Scientist, Canadian Blood Services

Quick Facts
Today’s announcement is for $1.3 million in funding for glycomics research and an additional $2.6 million in co-funding from research partners and industry collaborators across Canada.
This funding will support four new projects within GlycoNet’s Collaborative Team Grant, one Clinical Partnership Grant, five Strategic Initiatives Grant, and one Translational Grant.
Since 2015, GlycoNet has leveraged $24.2 million from the federal NCE program into a total investment of $49.7 million in R&D, supported the training of over 450 highly qualified personnel and spun-out five new Canadian companies.